More Articles


Invest in MSLs to reap bigger gains

Andrew Stone, (Dec 31, 2019)

To get the most from MSLs pharma needs to invest, measure and empower

Telemedicine: The future of clinical trials?

Nicola Davies, (Dec 13, 2019)

There is a new surge of interest in telemedicine’s potential to optimize clinical trials, but is this what patients want?
Patients and Medical

Patients united: Bringing the patient voice to genetics research

Nicola Davies, (Dec 5, 2019)

Parkinson’s disease genetic research has a powerful force to hand – an army of patients

Five eye-openers from the MIT Healthcare Panel

Paul Schrimpf, (Nov 28, 2019)

Modern pharma should not underestimate the importance of experience and culture in this age of innovation in R&D and data science
Access and Evidence

Prescription drug pricing: The times they are a changin’

Ulrich Neumann, (Nov 25, 2019)

The political mood in the US on drug pricing at a national and state level is putting the pressure on pharma to demonstrate value

Has direct to consumer marketing in pharma had its day?

Lucy Fulford, (Nov 25, 2019)

Outmoded and cliched DTC campaigns may be harming not helping pharma in the US

Clinical must think outside, and inside the box

Paul Simms, (Nov 21, 2019)

From site-in-a-box to virtual/siteless trials: which new model will successfully disrupt clinical research?

The online health trends pharma should be tapping into

Andrew Stone, (Nov 20, 2019)

Pharma should be harnessing some powerful online trends but is it?

Taking the plunge into digital

Andrew Stone, (Nov 13, 2019)

Medical affairs is starting to expand its knowledge, reach and engagement with digital tools
Access and Evidence

Putting a price on life: Is the answer outside pharma?

Nicola Davies, (Nov 4, 2019)

Gene replacement and cell-based therapies are here to cure, but are we ready for them? The current difficulty pricing groundbreaking healthcare advancements suggests maybe not.